Those with PCOS may be more likely to experience this type of cycle change, which is also in line with previous research where GLP-1 medications have shown some promise for improving menstrual cycle regularity in women with PCOS
Significant weight loss is typically observable by this point
Contact your healthcare provider if you experience: Severe or worsening abdominal pain , particularly if it is persistent, sharp, or localized to a specific area Bloating accompanied by persistent vomiting , especially if you are unable to keep down fluids or medications Signs of gastroparesis (severely delayed gastric emptying), including feeling full after eating only small amounts, persistent nausea, vomiting undigested food several hours after eating, or unintentional weight loss beyond expected therapeutic effects Symptoms suggesting bowel obstruction or ileus , such as inability to pass gas or stool, severe abdominal distension, or cramping pain Blood in vomit or stool , which could indicate gastrointestinal bleeding Signs of pancreatitis , including severe, persistent upper abdominal pain that may radiate to the back, accompanied by nausea and vomiting Right upper quadrant pain, fever, or yellowing of the skin or eyes , which could indicate gallbladder disease (cholelithiasis or cholecystitis), a known risk with GLP-1 receptor agonists Signs of dehydration such as excessive thirst, dry mouth, dizziness, or decreased urination, which could lead to acute kidney injury if severe Additionally, seek medical advice if bloating significantly impairs your quality of life or prevents you from maintaining adequate nutrition and hydration
Keep in mind that when traveling with medication, the Transportation Security Administration (TSA) may take you aside to inspect your bags
Safe Transport Practices for Maintaining Optimal Temperature Semaglutide requires specific temperature conditions to maintain its stability
But individuals starting semaglutide who are also dealing with GI side effects, reduced food and fluid intake, and the physiological stress of early dose escalation may notice this elevated baseline more acutely than someone in a controlled trial environment
